Tech Company Financing Transactions

G1 Therapeutics Funding Round

G1 Therapeutics secured a $12.5 million Series A funding round on 10/16/2013. Investors included MedImmune Ventures, Hatteras Venture Partners and Mountain Group Capital.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

700 Park Offices Dr. 200
Research Triangle Park, NC 27709
USA

Phone

919-213-9835

Website

www.g1therapeutics.com

Email Address

[email protected]

Overview

G1 Therapeutics (Nasdaq: GTHX) is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Mark Velleca

        

Chief Medical Officer

Raj Malik

        

Chief Scientific Officer

Jay Strum

        

VP - Bus. Development

Mark Avagliano

        

VP - Bus. Development

John Demaree

        

VP - Operations

Terry Murdock

        

Browse more venture capital transactions:

Prev: 10/16/2013: 1366 Technologies venture capital transaction
Next: 10/16/2013: Cardiac Dimensions venture capital transaction

Share this article

News on VC Transactions

We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary